Aspen Aerogels Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Aspen Aerogels han disminuido a una tasa media anual de -49.6%, mientras que en la industria Chemicals los beneficios crecieron en un 3.7% anualmente. Los ingresos han ido creciendo a una tasa media de 29.4% al año.
Información clave
-49.65%
Tasa de crecimiento de los beneficios
-23.03%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 12.93% |
| Tasa de crecimiento de los ingresos | 29.44% |
| Rentabilidad financiera | -165.40% |
| Margen neto | -143.69% |
| Próxima actualización de resultados | 07 May 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
ASPN: GM Demand Reset And Tough Outlook Will Pressure Shares
Analysts have cut their average price targets on Aspen Aerogels to a range of about $3 to $6. This reflects weaker near term expectations tied to GM related EV softness, offset by company efforts to protect cash, reduce costs, and focus on longer term platform value.
ASPN: Cost Discipline And GM Settlement Cash Will Support Future Upside
Analysts have reduced their average price targets on Aspen Aerogels to a range of about $3 to $6, citing Q4 earnings and guidance shortfalls, ongoing softness tied to GM and the broader EV reset, as well as a sharper company focus on cash preservation and cost controls. Analyst Commentary Across recent research notes, analysts broadly cut price targets on Aspen Aerogels following Q4 results and softer guidance, but the tone is mixed rather than uniformly negative.ASPN: Cost Actions And Cash Support Will Drive Long-Term Upside Potential
Analysts have reduced the fair value estimate for Aspen Aerogels from $10 to $6, reflecting lower price targets across the Street as they weigh weaker GM related EV demand against the company's cost actions, cash support from the GM settlement, and longer term platform potential. Analyst Commentary Street research has shifted sharply lower on headline price targets, but the tone is not uniformly negative.ASPN: Tough Year And GM Demand Reset Will Pressure Shares
Narrative Update: Aspen Aerogels The analyst price target for Aspen Aerogels has moved from $6.00 to $3.00 as analysts factor in a tough year following a Q4 earnings miss and softer guidance, partly offset by cost actions and a stronger net cash position tied to the GM settlement. Analyst Commentary Bearish analysts have reset expectations for Aspen Aerogels, cutting price targets across the board after the Q4 earnings miss and softer near term guidance.Aspen Aerogels: A Long Road Ahead
Feb 27ASPN: Updated Profitability Assumptions Will Still Support Long-Term Upside Potential
Analysts have lifted their price target for Aspen Aerogels to $10.00, citing updated inputs around revenue growth, profit margins, and future P/E assumptions as the key drivers of this change. Valuation Changes Fair Value: revised slightly from $9.98 to $10.00 per share, aligning with the updated price target.
ASPN: Higher 2025 Loss Guidance Will Still Support Long-Term Opportunity
Analysts have adjusted their price target on Aspen Aerogels, highlighting a slightly higher discount rate and future P/E assumptions, along with modest tweaks to revenue growth and profit margin expectations, as they reassess the risk and earnings profile embedded in their valuation models. What's in the News Aspen Aerogels revised full year 2025 revenue guidance to a range of $270 million to $280 million, compared with prior guidance of $297 million to $317 million (company guidance).Aspen Aerogels, Inc.'s (NYSE:ASPN) 32% Share Price Surge Not Quite Adding Up
Jan 23
ASPN: Lower 2025 Guidance Will Still Support Long-Term Upside Potential
Analysts have raised their price targets on Aspen Aerogels, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that together suggest a modest improvement in their overall outlook for the shares. What's in the News Aspen Aerogels revised its full-year 2025 revenue guidance to a range of US$270 million to US$280 million, compared with prior guidance of US$297 million to US$317 million (company guidance).ASPN: Lower 2025 Outlook Will Still Support Attractive Long-Term Upside Potential
Analysts have lifted their price target on Aspen Aerogels to reflect updated assumptions around revenue growth, profit margins, discount rate and future P/E. The new target implies a valuation aligned with these revised inputs compared with the prior figure.ASPN: Reduced Guidance And Higher Discount Rate Will Present Long-Term Upside Opportunity
Aspen Aerogels' consensus analyst price target has been reduced by approximately $4.02 per share, as analysts temper their assumptions for revenue growth and profit margins, while also applying a slightly higher discount rate and multiple to future earnings. What's in the News Aspen Aerogels lowered its full year 2025 revenue guidance to a range of $270 million to $280 million, down from prior expectations of $297 million to $317 million (Key Developments).ASPN: Improving Risk Profile Will Support Long-Term Opportunity Despite Wider Losses
Analysts have raised their price target on Aspen Aerogels by a modest amount, now embedding slightly lower discount rates and marginally softer future valuation multiples, as they emphasize the company’s improving risk profile and steady long term growth outlook. What's in the News Aspen Aerogels lowered its full year 2025 revenue guidance to a range of $270 million to $280 million, down from the prior outlook of $297 million to $317 million (company guidance).Aspen Aerogels (NYSE:ASPN) Might Have The Makings Of A Multi-Bagger
Dec 04ASPN: Lower Profit Margins Will Drive Opportunity As Net Losses Peak
Analysts have lowered their price target for Aspen Aerogels from $8.75 to $6.83 per share. They cite revised expectations for slower revenue growth and profit margins.ASPN: Reduced EV Tax Credits Will Challenge Thermal Segment Performance Ahead
Analysts have lowered their price target for Aspen Aerogels from $9.58 to $8.75. They cited reduced electric vehicle production forecasts and increased macroeconomic pressures on the company’s key Thermal Barrier business segment.Optimistic Investors Push Aspen Aerogels, Inc. (NYSE:ASPN) Shares Up 27% But Growth Is Lacking
Oct 11Aspen Aerogels, Inc. (NYSE:ASPN) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 09Cost Optimization And Industrial Demand Will Shape Future Markets
The consensus price target for Aspen Aerogels has increased, reflecting a higher valuation multiple (future P/E rising from 14.46x to 20.08x) despite a notable decline in net profit margin (from 14.47% to 11.75%), resulting in a new fair value estimate of $9.75. What's in the News Ricardo Rodriguez will step down as CFO at the end of Q3 and be succeeded by Grant Thoele, who currently serves as Chief of Staff and VP of Corporate Strategy and Finance.Aspen Aerogels, Inc.'s (NYSE:ASPN) Shares Climb 28% But Its Business Is Yet to Catch Up
Aug 06Is Aspen Aerogels (NYSE:ASPN) A Risky Investment?
Jul 09Aspen Aerogels, Inc.'s (NYSE:ASPN) 29% Share Price Surge Not Quite Adding Up
Jun 11Not Many Are Piling Into Aspen Aerogels, Inc. (NYSE:ASPN) Stock Yet As It Plummets 30%
Apr 17Aspen Aerogels (NYSE:ASPN) Has A Pretty Healthy Balance Sheet
Apr 01Aspen Aerogels: Tariffs, Tesla And The Silver Lining
Mar 31Positive Sentiment Still Eludes Aspen Aerogels, Inc. (NYSE:ASPN) Following 34% Share Price Slump
Feb 28Aspen Aerogels: Insulation Play Leaves Investors In The Cold
Feb 14Aspen Aerogels (NYSE:ASPN) Is Looking To Continue Growing Its Returns On Capital
Feb 14Aspen Aerogels: There Are Reasons To Be Careful But It's So Cheap
Dec 23Aspen Aerogels: Thermal Barriers Could Sustain Further Growth Despite A Chilly Market
Dec 02Aspen Aerogels: Despite Recent Pressure, This Is Intriguing
Nov 17With A 32% Price Drop For Aspen Aerogels, Inc. (NYSE:ASPN) You'll Still Get What You Pay For
Nov 07Aspen Aerogels: Interesting Times
Oct 28Aspen Aerogels (NYSE:ASPN) Is Looking To Continue Growing Its Returns On Capital
Oct 17Aspen Aerogels: Current Valuation Is Not A Good Risk/Reward
Sep 26Aspen Aerogels: Management Guidance Remains Very Conservative
Sep 18
Decisive Expansion And EV Innovations Propel Aerogel Giant Towards Financial Triumph
Expansion of production capacity and strategic financial management shows promise for significant revenue growth and improved net income through cost efficiency.Why Investors Shouldn't Be Surprised By Aspen Aerogels, Inc.'s (NYSE:ASPN) 32% Share Price Surge
Aug 24Investors Shouldn't Be Too Comfortable With Aspen Aerogels' (NYSE:ASPN) Earnings
Aug 15Aspen Aerogels: Impressive, But Some Questions As Well
Aug 12Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Aspen Aerogels. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 271 | -390 | 84 | 13 |
| 30 Sep 25 | 353 | -305 | 89 | 15 |
| 30 Jun 25 | 397 | -312 | 96 | 17 |
| 31 Mar 25 | 437 | -286 | 103 | 18 |
| 31 Dec 24 | 453 | 13 | 107 | 18 |
| 30 Sep 24 | 414 | 1 | 104 | 18 |
| 30 Jun 24 | 357 | 1 | 101 | 17 |
| 31 Mar 24 | 288 | -31 | 95 | 17 |
| 31 Dec 23 | 239 | -46 | 90 | 16 |
| 30 Sep 23 | 214 | -55 | 85 | 16 |
| 30 Jun 23 | 190 | -71 | 78 | 17 |
| 31 Mar 23 | 188 | -80 | 74 | 17 |
| 31 Dec 22 | 180 | -83 | 67 | 17 |
| 30 Sep 22 | 152 | -89 | 59 | 16 |
| 30 Jun 22 | 146 | -68 | 53 | 14 |
| 31 Mar 22 | 132 | -50 | 45 | 13 |
| 31 Dec 21 | 122 | -37 | 39 | 11 |
| 30 Sep 21 | 113 | -27 | 35 | 10 |
| 30 Jun 21 | 107 | -26 | 30 | 9 |
| 31 Mar 21 | 100 | -25 | 28 | 9 |
| 31 Dec 20 | 100 | -22 | 27 | 9 |
| 30 Sep 20 | 124 | -17 | 29 | 9 |
| 30 Jun 20 | 135 | -12 | 31 | 9 |
| 31 Mar 20 | 140 | -12 | 31 | 9 |
| 31 Dec 19 | 139 | -15 | 32 | 8 |
| 30 Sep 19 | 129 | -28 | 33 | 8 |
| 30 Jun 19 | 117 | -32 | 32 | 7 |
| 31 Mar 19 | 109 | -34 | 33 | 7 |
| 31 Dec 18 | 104 | -34 | 33 | 6 |
| 30 Sep 18 | 105 | -22 | 30 | 6 |
| 30 Jun 18 | 108 | -19 | 30 | 6 |
| 31 Mar 18 | 112 | -17 | 30 | 6 |
| 31 Dec 17 | 112 | -19 | 32 | 6 |
| 30 Sep 17 | 103 | -23 | 32 | 6 |
| 30 Jun 17 | 105 | -23 | 33 | 6 |
| 31 Mar 17 | 108 | -19 | 32 | 6 |
| 31 Dec 16 | 118 | -12 | 29 | 5 |
| 30 Sep 16 | 127 | -5 | 28 | 5 |
| 30 Jun 16 | 129 | -4 | 27 | 5 |
| 31 Mar 16 | 132 | -5 | 27 | 5 |
| 31 Dec 15 | 123 | -6 | 26 | 5 |
| 30 Sep 15 | 113 | -11 | 25 | 6 |
| 30 Jun 15 | 107 | -11 | 25 | 6 |
Ingresos de calidad: ASPN actualmente no es rentable.
Margen de beneficios creciente: ASPN actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ASPN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 49.6% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ASPN en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: ASPN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Chemicals (0.1%).
Rentabilidad financiera
Alta ROE: ASPN tiene una rentabilidad financiera negativa (-165.4%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/04/30 05:00 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Aspen Aerogels, Inc. está cubierta por 16 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Benjamin Kallo | Baird |
| J. David Anderson | Barclays |
| J. David Anderson | Barclays |